OSAKA SODA CO.,LTD. (4046) Stock Price

Osaka Soda operates through multiple business segments including basic chemicals, functional chemicals, healthcare, and trading divisions, providing a diverse range of products and services.

The basic chemicals segment manufactures and sells caustic soda, hydrochloric acid, and liquefied chlorine. These products are sometimes distributed through subsidiary Daiso Chemical Co., Ltd.

The functional chemicals segment manufactures and sells allyl ethers and epichlorohydrin rubber. Daiso Engineering Co., Ltd. manufactures and sells electrodes, while the company also invests in specialty chemicals operations in North America.

The healthcare segment manufactures and sells pharmaceutical purification materials and pharmaceutical active ingredients and intermediates. Related companies include Sanyo Fine Co., Ltd. and DAISO Fine Chem USA, Inc.

The trading division purchases and sells paint raw materials and adhesive raw materials. The company also engages in electronic materials trading, logistics, and resource recycling operations.

Osaka Soda aims to realize a secure and prosperous society through innovative technologies and products. As a chemical company group that creates new value through chemistry, the company promotes manufacturing that considers the environment and safety, and meets customer needs with globally competitive technology and quality.

Under its medium-term management plan "Shape the Future-2025," the company has established three core strategies: strengthening the foundation of existing businesses, enhancing new product development capabilities, and advancing sustainability management. Through these initiatives, the company is expanding its business foundation by generating stable cash flows and investing in growth areas.

In the basic chemicals business, the company is improving production efficiency and reducing costs to strengthen its high-margin business base. In the specialty chemicals business, the company is deepening market penetration in synthetic resins and synthetic rubbers, developing new applications, and considering capacity expansion to increase its market presence in allyl ethers.

In the healthcare business, the company is expanding production facilities for pharmaceutical-grade materials to meet growing demand for diabetes and obesity treatment drugs. The company is also pursuing entry into the biopharmaceutical sector, with plans to expand its portfolio into mid-sized molecule areas such as nucleic acid therapeutics.

To strengthen new product development capabilities, the company is focusing on four areas: environment and energy, mobility, information and communications, and health and healthcare. In particular, the company is accelerating development of next-generation battery materials and automotive new-normal materials, targeting early market launch.

In advancing sustainability management, the company is working to strengthen corporate governance and implement environmental impact reduction measures to achieve both a sustainable society and enhanced corporate value. Through these efforts, the company is deepening dialogue with stakeholders and enhancing corporate value.